Is Sermorelin Legal in Oregon?

Print or save as PDF

Key numbers

  • 0.05 mgStrength of Geref's diagnostic ampule, a withdrawn sermorelin approval; no sermorelin product is FDA-approved nowSource: federalregister.gov, as cited Nov 7, 2026
  • 30 micrograms per kgHistorical pediatric dose in Geref's program; not a current recommendationSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 14 daysLength of historical older-men study dosing; not a current recommendationSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Sermorelin

  • Federal approval / None current; Geref's approvals were withdrawn effective June 18, 2009 [1]
  • What is sold now / Compounded sermorelin, which FDA does not review for safety, effectiveness or quality [2]
  • FDA safety-risk list / Sermorelin is not listed among bulk substances FDA says may present significant safety risks [3]
  • Outsourcing-facility list / Sermorelin acetate is nominated in category 1, under evaluation [4]
  • State-licensed pharmacy list / Sermorelin does not appear in any category [5]
  • Sport / Prohibited at all times by WADA, in and out of competition [6]
  • Historic approved uses / Pediatric growth hormone deficiency and a pituitary diagnostic test only [1]

The short answer

No sermorelin product is currently FDA-approved, and products sold today are compounded [1][2]. Federal compounding rules apply to those products. Whether a particular prescription or sale is lawful in Oregon also depends on Oregon's own rules, which are separate from the federal picture below.

Why no sermorelin product is FDA-approved today

Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone, the shortest synthetic peptide with the full biological activity of GHRH. It acts on the pituitary to trigger the body's own growth hormone release; it is not growth hormone [7].

Geref held two approvals: a 0.05 mg/ampule product approved December 28, 1990 for evaluating the pituitary's ability to secrete growth hormone, and 0.5 mg and 1 mg vials approved September 26, 1997 for treating idiopathic growth hormone deficiency in children with growth failure [1]. EMD Serono discontinued both in 2008 and asked FDA to withdraw the applications; FDA withdrew the approvals effective June 18, 2009 [1]. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness [1].

With Geref gone, sermorelin products in the US today are compounded, not FDA-approved [2].

Where sermorelin sits on FDA's compounding lists

  • Sermorelin is not on FDA's list of bulk substances that may present significant safety risks when compounded [3].
  • On FDA's list of nominated bulk substances for outsourcing facilities (updated March 21, 2025), sermorelin acetate sits in category 1, under evaluation, and is marked as a component of FDA-approved drugs [4]. Being nominated for evaluation is a pending status; it is not an approval.
  • Sermorelin does not appear in any category on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) [5].
  • It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [8].

Prescriptions and compounding

FDA says compounded drugs are not FDA-approved and that it does not review their safety, effectiveness or quality before they reach patients [9][2]. FDA's compounding page says pharmacy compounding under the federal exemption requires a valid patient-specific prescription, while registered outsourcing facilities may also distribute compounded drugs on an order from a health care provider, such as for office stock [9].

There is no current approved dose. In the pediatric program that supported Geref, the dose was 30 micrograms per kg once daily subcutaneously at bedtime [10]; in a study of older men it was 0.5 mg or 1 mg subcutaneously twice daily for 14 days [11]. Those are historical research doses, not recommendations.

Questions worth asking

Choose the questions you want to keep

Is sermorelin legal in sport?

No. WADA's 2026 Prohibited List names sermorelin in S2.2.4 (growth hormone releasing factors) and prohibits it at all times, in and out of competition [6]. It is also named in the 2027 List, which takes effect January 1, 2027 [12].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. Is any sermorelin product currently FDA-approved, according to the article?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is sermorelin legal in Oregon?
No sermorelin product is currently FDA-approved, so sermorelin sold today is compounded [1][2]. Oregon's own prescribing and pharmacy rules are a separate question from federal approval status.
Is sermorelin FDA-approved?
Not any more. Geref's 0.05 mg diagnostic product and its 0.5 mg and 1 mg vials were approved in 1990 and 1997, then withdrawn effective June 18, 2009 at the manufacturer's request [1].
Why did Geref leave the market?
The manufacturer discontinued it in 2008 and asked FDA to withdraw the applications, which FDA did in 2009. In 2013 FDA determined it was not withdrawn for reasons of safety or effectiveness [1].
Does compounded sermorelin require a prescription?
FDA says pharmacy compounding under the federal exemption requires a valid patient-specific prescription. Registered outsourcing facilities may also supply compounded drugs on a provider's order without an individual patient prescription [9].
Is sermorelin banned in sport?
Yes. WADA names sermorelin in S2.2.4 of its Prohibited List and prohibits it at all times, in and out of competition [6].
What was Geref approved to treat?
Only two uses: evaluating the pituitary's ability to secrete growth hormone, and treating idiopathic growth hormone deficiency in children with growth failure. It was not approved for adults, anti-aging, weight loss or athletic performance [1].
Show all 12 referencesHide references
  1. Federal Register :: Request Access.
  2. Official web page.
  3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  4. U.S. Food and Drug Administration.
  5. U.S. Food and Drug Administration.
  6. World Anti-Doping Agency.
  7. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
  8. Official web page.
  9. Human Drug Compounding Laws | FDA.
  10. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
  11. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
  12. World Anti-Doping Agency.
Sermorelin legal Oregon: evidence summary chart
Image: HealthRX.com. Full sermorelin legal Oregon guide and sources at healthrx.com/peptide-legal-sermorelin.